文献速递冠心病血脂与心血管预防

急性冠脉综合征后早期强化降脂的流程化实施:BRIDGE试验

Protocol-Based Implementation of Early Intensive Lipid Management After Acute Coronary Syndrome: The BRIDGE Trial.
PubMed 文献 · J Am Coll Cardiol · 2026-08-31

BRIDGE试验为集群随机研究,纳入330例急性冠脉综合征患者,比较基于预设算法的流程化降脂管理与标准管理。6个月时流程化组LDL-C<70 mg/dL达标率86.4% vs 73.7%(差异12.6个百分点,P=0.005),LDL-C<55 mg/dL达标率60.8% vs 34.5%(差异26.3个百分点,P<0.001),支持结构化算法路径改善指南推荐降脂目标的实现。

要点

  • 流程化降脂策略显著提高ACS后6个月LDL-C<70 mg/dL达标率。
  • 流程化策略大幅提升LDL-C<55 mg/dL达标率,差异达26.3个百分点。
  • 流程化组高强度他汀、依折麦布和PCSK9抑制剂使用率更高。

核心结论

  • 基于预设算法的早期强化降脂流程化实施策略显著改善了ACS后指南推荐LDL-C目标的达标情况。

研究设计与样本

  • 集群随机试验,10个中心按1:1随机分配至流程化降脂管理或标准降脂管理。
  • 2024年11月至2025年7月共纳入330例ACS患者,1例撤回知情同意后研究人群为329例。
  • 主要疗效分析纳入315例具有完整6个月LDL-C数据的患者。

主要发现

  • 6个月时LDL-C<70 mg/dL达标率流程化组86.4% vs 标准组73.7%,组间差异12.6个百分点(95%CI:3.8-21.5个百分点;P=0.005)。
  • 医院水平敏感性分析中,LDL-C<70 mg/dL达标率组间差异为12.8个百分点(95%CI:-2.0至27.6个百分点;P=0.08)。
  • 6个月时LDL-C<55 mg/dL达标率流程化组60.8% vs 标准组34.5%,组间差异26.3个百分点(95%CI:18.5-34.0个百分点;P<0.001)。
  • 6个月时流程化组高强度他汀、依折麦布和PCSK9抑制剂的使用率均高于标准组。

关键数值与推荐

  • 流程化组以LDL-C约55 mg/dL作为方案规定的强化治疗操作阈值,两组治疗目标均为LDL-C<70 mg/dL。
  • 流程化组根据基线降脂治疗状态和LDL-C水平,按预设算法在住院期间启动或强化高强度他汀、依折麦布和PCSK9抑制剂治疗。
  • 第4周复查LDL-C,必要时升级治疗。

临床怎么用

  • 对ACS患者可采用结构化、基于算法的护理路径,以促进早期启动和强化降脂治疗。
  • 流程化策略有助于在常规临床实践中落实指南推荐的降脂管理。

局限性

  • 主要疗效分析仅纳入315例具有完整6个月LDL-C数据的患者,而非全部329例研究人群。
  • LDL-C<70 mg/dL达标率的医院水平敏感性分析结果未达统计学显著性(95%CI跨0,P=0.08)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although guideline-recommended intensive lipid-lowering therapy (LLT) reduces recurrent cardiovascular events after acute coronary syndrome (ACS), timely implementation of intensive LLT and achievement of low-density lipoprotein cholesterol (LDL-C) target remain suboptimal in routine clinical practice. OBJECTIVES: The purpose of this study was to determine whether a protocol-based implementation strategy improves timely achievement of guideline-recommended LDL-C target after ACS. METHODS: We conducted a cluster-randomized trial involving patients with ACS. Ten centers were randomly assigned 1:1 to protocol-based or standard lipid management. In the protocol-based group, LLT was initiated or intensified during the index hospitalization according to a prespecified algorithm based on baseline LLT status and LDL-C levels using high-intensity statins, ezetimibe, and PCSK9 inhibitors. LDL-C was reassessed at 4 weeks, with treatment escalation when indicated. In the protocol-based group, an LDL-C level of approximately 55 mg/dL was used as the protocol-specified operational threshold for intensification, whereas LDL-C <70 mg/dL was the treatment goal in both groups. The primary and key secondary endpoints were achievement of LDL-C <70 mg/dL and <55 mg/dL at 6 months, respectively. RESULTS: Between November 2024 and July 2025, 330 patients were enrolled, and 329 patients comprised the study population after 1 patient withdrew consent. The primary efficacy analysis included 315 patients with complete 6-month LDL-C data. Baseline characteristics were balanced between groups. The mean age was 69 years, 18% were women, and the median LDL-C level was 110 mg/dL. At 6 months, LDL-C <70 mg/dL was achieved in 86.4% vs 73.7% (between-group difference, 12.6 percentage points [95% CI: 3.8-21.5 percentage points]; P = 0.005); the corresponding difference was 12.8 percentage points (95% CI: -2.0 to 27.6 percentage points; P = 0.08) in a hospital-level sensitivity analysis. Similar findings were observed for LDL-C <55 mg/dL (60.8% vs 34.5%; between-group difference, 26.3 percentage points [95% CI: 18.5-34.0 percentage points]; P < 0.001). At 6 months, use of high-intensity statins, ezetimibe, and PCSK9 inhibitors was higher in the protocol-based group. CONCLUSIONS: A protocol-based implementation strategy for early intensive LLT significantly improved achievement of the guideline-recommended LDL-C target after ACS. These findings support a structured, algorithm-based care pathway to facilitate timely initiation and intensification of LLT and improve implementation of guideline-recommended lipid management in routine clinical practice. (Brief and Protocol-Based Intensive Lipid Management in Patients with Acute Coronary Syndrome; jRCT1020240029).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Oyama K, Takahashi J, Funaki T, et al. Protocol-Based Implementation of Early Intensive Lipid Management After Acute Coronary Syndrome: The BRIDGE Trial. J Am Coll Cardiol. 2026. PMID: 42671370. doi:10.1016/j.jacc.2026.08.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。